![]() Such factors include, among other things: risks and uncertainties relating to the Company's limited operating history and the need to comply with environmental and governmental regulations. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. They are not guarantees of future performance. These statements reflect management's current estimates, beliefs, intentions and expectations. Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. The operational expertise developed by the Company as a result of these efforts has created new market opportunities for the Company in white label sales. In addition, through its efforts to develop a better CannaStripsTM product, the Company has developed considerable expertise in cannabis extraction and nursery activities. From start to finish, the production process, based on the Company's technology, tests for quality and composition of all the ingredients used in each and every strip which results in a delivery system that is safe, consistent and effective. The technology provides a new way to accurately meter the dosage and assure the purity of selected product. Some strips will also include supplemental co-active ingredients such as nutraceuticals, vitamins and peptides. The Company's technology produces infused strips (similar to breath strips) that are not only a safer, healthier option to other forms of delivery but also superior bioavailability of cannabis constituents. is a technology company that licenses its technology to a state-of-the-art production and packaging facility located in Southern California. The encapsulation also is more effective in penetrating the blood-brain barrier and allowing for greater bioavailability and extending the effective time from a single dose.Ĭore One Labs Inc. This undetectability allows the material to avoid being filtered out of the blood stream by the liver. Once in the blood stream the encapsulation is undetectable as a foreign material by the liver. The Company's directors are currently conducting additional due diligence investigations with respect to the proposed acquisition.ĬannaStrips TM is a formulated oral strip for effective buccal mucosal delivery that disrupts the barrier created by saliva coating the mucosal membrane for the active materials (in this case cannabinoids) which have been nanoparticulated and encapsulated to penetrate the multiple layers of mucosal and sub-mucosal membranes to the blood stream. The shares to be issued to the current shareholders of Rainy Daze are not expected to be subject to restrictions on transfer upon their issuance.Ĭlosing of the acquisition of Rainy Daze is subject to the approval of the Company's directors. To acquire Rainy Daze, the Company has agreed to pay $100,000 in cash to the current shareholders of Rainy Daze, and to issue an aggregate of 3,500,000 common shares of the Company. Ltd., an arms-length company operating as "Rainy Daze Cannabis" ("Rainy Daze"). The Company has entered into a definitive agreement to acquire all of the issued and outstanding shares of 1210950 B.C. ![]() (CSE: COOL), (OTCQX: CLABF), ( Frankfurt: LD6, WKN: A14XHT) ("COOL" or the "Company") is issuing this news release to clarify the terms of its definitive agreement to acquire Rainy Daze Cannabis, which was announced on November 4, 2019. ![]() 5, 2019 /PRNewswire/ - Core One Labs Inc.
0 Comments
Leave a Reply. |